

**PROCESS FOR PREPARING N-BENZYL-3-HYDROXY-
4-SUBSTITUTED-PYRIDIN-2-(1H)-ONES**

PRIORITY

5 This Application claims the benefit of priority from United States Provisional Patent Application Serial No. 61/941,540, filed February 19, 2014, the entirety of which is incorporated herein by reference.

FIELD OF THE DISCLOSURE

10 Disclosed herein is a process for preparing N-benzyl-3-hydroxypyridin-2-(1*H*)-ones that are substituted at the pyridine ring 4-position with a 4-carbamoylpiperazin-1-yl moiety.

DETAILED DISCLOSURE

General Definitions

 In this specification and in the claims that follow, reference will be made to a number of terms, which shall be defined to have the following meanings:

15 All percentages, ratios and proportions herein are by weight, unless otherwise specified. All temperatures are in degrees Celsius (° C) unless otherwise specified.

 Throughout the description and claims of this specification the word “comprise” and other forms of the word, such as “comprising” and “comprises,” means including but not limited to, and is not intended to exclude, for example, other additives, components,
20 integers, or steps.


 As used in the description and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise.

 The antecedent “about” indicates that the values are approximate. For example the range of “about 1 equivalent (equiv.) to about 50 equivalents” indicates that the values are
25 approximate values. The range of “about 1 equivalent to about 50 equivalents” includes approximate and specific values, e.g., the range includes about 1 equivalent, 1 equivalent, about 50 equivalent and 50 equivalents.


 When a range is described, the range includes both the endpoints of the range as well as all numbers in between. For example, “between 1 equiv. and 10 equiv.” includes 1
30 equiv., 10 equiv. and all amounts between 1 equiv. and 10 equiv. Likewise, “from 1 equiv. to 10 equiv.” includes 1 equiv., 10 equiv. and all amounts between 1 equiv. and 10 equiv.

COMPOUNDS

The present disclosure provides a process for the preparation of compounds having the general formula:




wherein Y is a 4-carbamoylpiperazin-1-yl unit having the formula:




5

thereby providing a compound having the formula:




wherein R¹ is defined herein. Z is a substituted or unsubstituted phenyl ring having the formula:

10




the index n is an integer from 0 to 5.

As such, the compounds that can be prepared by the disclosed process are also represented by the formula:



R units when present represent from 1 to 5 substitutions for a hydrogen atom on the indicated phenyl ring. As such, the index n is an integer from 1 to 5 when one or more substitutions are present. When the index n is 0, R is absent and therefore there are no substitutions for hydrogen and the resulting subgenus is represented by the formula:



R Units

R units are independently chosen from:


- i) C₁-C₆ linear, C₃-C₆ branched or C₃-C₆ cyclic alkyl. Non-limiting examples of C₁-C₄ linear alkyl units include methyl (C₁), ethyl (C₂), n-propyl (C₃), n-butyl (C₄), n-pentyl (C₅) and n-hexyl (C₆). Non-limiting examples of C₃-C₆ branched and C₃-C₆ cyclic alkyl units include *iso*-propyl (C₃), cyclopropyl (C₃), *sec*-butyl (C₄), *iso*-butyl (C₄), *tert*-butyl (C₄), cyclobutyl (C₄), *neo*-pentyl (C₅), cyclopentyl (C₅), *iso*-hexyl (C₆), cyclohexyl (C₆), and the like;
- ii) C₁-C₆ linear, C₃-C₆ branched or C₃-C₆ cyclic alkoxy. Non-limiting examples of C₁-C₄ linear alkoxy units include methoxy (C₁), ethoxy (C₂), n-propoxy (C₃), n-butoxy (C₄), n-pentyloxy (C₅) and n-hexyloxy (C₆). Non-limiting examples of C₃-C₆ branched and C₃-C₆ cyclic alkoxy units include *iso*-propoxy (C₃), cyclopropoxy (C₃), *sec*-butoxy (C₄), *iso*-butoxy (C₄), *tert*-

butoxy (C₄), cyclobutoxy (C₄), neopentyloxy (C₅), cyclopentyloxy (C₅), isohexyloxy (C₆), cyclohexyloxy (C₆), and the like;

iii) halogen, wherein each R unit comprising a halogen is independently chosen from fluoro, chloro, bromo or iodo; or

5 iv) cyano.

One aspect of the disclosure relates to compounds wherein the index n is equal to 0 and therefore R unit substitutions are absent therefore resulting in a subgenus having the formula:



10 Another aspect of the disclosure relates to compounds wherein the index n is equal to 1. One embodiment of this aspect relates to compounds wherein R is a halogen. The following are non-limiting examples of this embodiment wherein Z units are chosen from 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-bromophenyl, 3-bromophenyl, 4-bromophenyl, 2-iodophenyl, 3-iodophenyl, and 4-iodophenyl.

In one iteration of this embodiment, Z is 4-chlorophenyl.

Another embodiment of this aspect relates to compounds wherein R is chosen from one or more C₁-C₆ linear alkyl units. Non-limiting examples of this embodiment are Z units chosen from 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 2-ethylphenyl, 3-ethylphenyl, 4-ethylphenyl, 2-(n-propyl)phenyl, 3-(n-propyl)phenyl, 4-(n-propyl)phenyl, 2-(n-butyl)phenyl, 3-(n-butyl)phenyl, 4-(n-butyl)phenyl, 2-(n-pentyl)phenyl, 3-(n-pentyl)phenyl, 4-(n-pentyl)phenyl, 2-(n-hexyl)phenyl, 3-(n-hexyl)phenyl, and 4-(n-hexyl)phenyl.

25 A further embodiment of this aspect relates to compounds wherein R is chosen from one or more C₃-C₆ branched alkyl units. Non-limiting examples of this embodiment are Z units chosen from 2-(*iso*-propyl)phenyl, 3-(*iso*-propyl)phenyl, 4-(*iso*-propyl)phenyl, 2-(*iso*-

butyl)phenyl, 3-(*iso*-butyl)phenyl, 4-(*iso*-butyl)phenyl, 2-(*sec*-butyl)phenyl, 3-(*sec*-butyl)phenyl, 4-(*sec*-butyl)phenyl, 2-(*tert*-butyl)phenyl, 3-(*tert*-butyl)phenyl, 4-(*tert*-butyl)phenyl, 2-(*iso*-pentyl)phenyl, 3-(*iso*-pentyl)phenyl, 4-(*iso*-pentyl)phenyl, 2-(*iso*-hexyl)phenyl, 3-(*iso*-hexyl)phenyl, and 4-(*iso*-hexyl)phenyl.

- 5 A still further embodiment of this aspect relates to compounds wherein R is chosen from one or more C₁-C₆ linear alkoxy units. Non-limiting examples of this embodiment are Z units chosen from 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-ethoxyphenyl, 3-ethoxyphenyl, 4-ethoxyphenyl, 2-(*n*-propoxy)phenyl, 3-(*n*-propoxy)phenyl, 4-(*n*-propoxy)phenyl, 2-(*n*-butoxy)phenyl, 3-(*n*-butoxy)phenyl, 4-(*n*-butoxy)phenyl, 2-(*n*-pentyloxy)phenyl, 3-(*n*-pentyloxy)phenyl, 4-(*n*-pentyloxy)phenyl, 2-(*n*-hexyloxy)phenyl, 3-(*n*-hexyloxy)phenyl, and 4-(*n*-hexyloxy)phenyl.

- 15 A yet further embodiment of this aspect relates to compounds wherein R is chosen from one or more C₃-C₆ branched alkoxy units. Non-limiting examples of this embodiment are Z units chosen from 2-(*iso*-propoxy)phenyl, 3-(*iso*-propoxy)phenyl, 4-(*iso*-propoxy)phenyl, 2-(*iso*-butoxy)phenyl, 3-(*iso*-butoxy)phenyl, 4-(*iso*-butoxy)phenyl, 2-(*sec*-butoxy)phenyl, 3-(*sec*-butoxy)phenyl, 4-(*sec*-butoxy)phenyl, 2-(*tert*-butoxy)phenyl, 3-(*tert*-butoxy)phenyl, 4-(*tert*-butoxy)phenyl, 2-(*iso*-pentyloxy)phenyl, 3-(*iso*-pentyloxy)phenyl, 4-(*iso*-pentyloxy)phenyl, 2-(*iso*-hexyloxy)phenyl, 3-(*iso*-hexyloxy)phenyl, and 4-(*iso*-hexyloxy)phenyl.

- 20 A further aspect of the disclosure relates to compounds wherein the index n is greater than 1. One embodiment of this aspect relates to compounds wherein R is a halogen. The following are non-limiting examples of this embodiment wherein Z units are chosen from 2,3-difluorophenyl, 2,4-difluorophenyl, 2,5-difluorophenyl, 2,6-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2,3,4-trifluorophenyl, 2,3,5-trifluorophenyl, 2,4,6-trifluorophenyl, 3,4,5-trifluorophenyl, 2,3,4,5-tetrafluorophenyl, 2,3,4,6-tetra-fluorophenyl, 2,3,4,5,6-pentafluorophenyl, 2,3-dichlorophenyl, 2,4-dichlorophenyl, 2,5-dichlorophenyl, 2,6-dichlorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 2,3,4-trichlorophenyl, 2,3,5-trichlorophenyl, 2,4,6-trichlorophenyl, 3,4,5-trichlorophenyl, 2,3,4,5-tetrachlorophenyl, 2,3,4,6-tetra-chlorophenyl, 2,3,4,5,6-pentachlorophenyl, 2,3-dibromophenyl, 2,4-dibromophenyl, 2,5-dibromophenyl, 2,6-dibromophenyl, 3,4-dibromophenyl, 3,5-dibromophenyl, 2,3,4-tribromophenyl, 2,3,5-tribromophenyl, 2,4,6-tribromophenyl, 3,4,5-tribromophenyl, 2,3,4,5-tetrabromophenyl, 2,3,4,6-tetra-bromophenyl, 2,3,4,5,6-pentabromophenyl, 2,3-diiodophenyl, 2,4-

diiodophenyl, 2,5-diiodophenyl, 2,6-diiodophenyl, 3,4-diiodophenyl, 3,5-diiodophenyl, 2,3,4-triiodophenyl, 2,3,5-triiodophenyl, 2,4,6-triiodophenyl, 3,4,5-triiodophenyl, 2,3,4,5-tetraiodophenyl, 2,3,4,6-tetra-iodophenyl, and 2,3,4,5,6-pentaiodophenyl.

Another embodiment of this aspect relates to compounds wherein R is a C₁-C₆ linear alkyl. The following are non-limiting examples of this embodiment wherein Z units are chosen from 2,3-dimethylphenyl, 2,4-dimethylphenyl, 2,5-dimethylphenyl, 2,6-dimethylphenyl, 3,4-dimethylphenyl, 3,5-dimethylphenyl, 2,3,4-trimethylphenyl, 2,3,5-trimethylphenyl, 2,4,6-trimethylphenyl, 3,4,5-trimethylphenyl, 2,3,4,5-tetramethylphenyl, 2,3,4,6-tetra-methylphenyl, 2,3,4,5,6-pentamethylphenyl, 2,3-diethylphenyl, 2,4-diethylphenyl, 2,5-diethylphenyl, 2,6-diethylphenyl, 3,4-diethylphenyl, 3,5-diethylphenyl, 2,3,4-triethylphenyl, 2,3,5-triethylphenyl, 2,4,6-triethylphenyl, 3,4,5-triethylphenyl, 2,3,4,5-tetraethylphenyl, 2,3,4,6-tetra-ethylphenyl, 2,3,4,5,6-pentaethylphenyl, 2,3-dibromophenyl, 2,4-dibromophenyl, 2,5-dibromophenyl, 2,6-dibromophenyl, 3,4-dibromophenyl, 3,5-dibromophenyl, 2,3,4-tri(n-propyl)phenyl, 2,3,5-tri(n-propyl)phenyl, 2,4,6-tri(n-propyl)phenyl, 3,4,5-tri(n-propyl)phenyl, 2,3,4,5-tetra(n-propyl)phenyl, 2,3,4,6-tetra-(n-propyl)phenyl, 2,3,4,5,6-penta(n-propyl)phenyl, 2,3-di(n-butyl)phenyl, 2,4-di(n-butyl)phenyl, 2,5-di(n-butyl)phenyl, 2,6-di(n-butyl)phenyl, 3,4-di(n-butyl)phenyl, 3,5-di(n-butyl)phenyl, 2,3,4-tri(n-butyl)phenyl, 2,3,5-tri(n-butyl)phenyl, 2,4,6-tri(n-butyl)phenyl, 3,4,5-tri(n-butyl)phenyl, 2,3,4,5-tetra(n-butyl)phenyl, 2,3,4,6-tetra(n-butyl)phenyl, and 2,3,4,5,6-penta(n-butyl)phenyl.

A still further aspect of the disclosure relates to compounds wherein the index n is greater than 1 and wherein at least one R is chosen from C₁-C₆ linear, C₃-C₆ branched or C₃-C₆ cyclic alkyl and at least one R is chosen from halogen.

A yet further aspect of the disclosure relates to compounds wherein the index n is greater than 1 and wherein at least one R is chosen from C₁-C₆ linear, C₃-C₆ branched or C₃-C₆ cyclic alkoxy and at least one R is chosen from halogen.

A still yet further aspect of the disclosure relates to compounds wherein the index n is greater than 1 and wherein at least one R is chosen from C₁-C₆ linear, C₃-C₆ branched or C₃-C₆ cyclic alkyl and at least one R is chosen from C₁-C₆ linear, C₃-C₆ branched or C₃-C₆ cyclic alkoxy.

30 R¹ Units

R¹ units are C₁-C₄ linear or C₃-C₄ branched alkyl. Non-limiting examples of C₁-C₄ linear alkyl units include methyl (C₁), ethyl (C₂), n-propyl (C₃), and n-butyl (C₄). Non-

limiting examples of C₃-C₆ branched alkyl units include *iso*-propyl (C₃), *sec*-butyl (C₄), *iso*-butyl (C₄) and *tert*-butyl (C₄).

In one embodiment R¹ is *tert*-butyl.

In another embodiment R¹ is methyl.

5 In a further embodiment R¹ is ethyl.

The following are non-limiting examples of compounds that can be prepared by the disclosed process:

Methyl 4-((1-(2-fluorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

10 Methyl 4-((1-(3-fluorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

Methyl 4-((1-(4-fluorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

15 Methyl 4-((1-(2,3-difluorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

Methyl 4-((1-(2,4-difluorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

Methyl 4-((1-(2,5-difluorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

20 Methyl 4-((1-(2,6-difluorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

Methyl 4-((1-(3,4-difluorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

25 Methyl 4-((1-(3,5-difluorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

Methyl 4-((1-(2-chlorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

Methyl 4-((1-(3-chlorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

30 Methyl 4-((1-(4-chlorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

Methyl 4-((1-(2,3-dichlorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

Methyl 4-((1-(2,4-dichlorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

Methyl 4-((1-(2,5-dichlorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

5 Methyl 4-((1-(2,6-dichlorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

Methyl 4-((1-(3,4-dichlorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

10 Methyl 4-((1-(3,5-dichlorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

Methyl 4-((1-(2-bromobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

Methyl 4-((1-(3-bromobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

15 Methyl 4-((1-(4-bromobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

Methyl 4-((1-(2,3-dibromobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

20 Methyl 4-((1-(2,4-dibromobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

Methyl 4-((1-(2,5-dibromobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

Methyl 4-((1-(2,6-dibromobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

25 Methyl 4-((1-(3,4-dibromobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

Methyl 4-((1-(3,5-dibromobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

30 Methyl 4-((1-(2-iodobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

Methyl 4-((1-(3-iodobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

Methyl 4-((1-(4-iodobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

Methyl 4-((1-(2,3-diiodobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

5 Methyl 4-((1-(2,4-diiodobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

Methyl 4-((1-(2,5-diiodobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

10 Methyl 4-((1-(2,6-diiodobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

Methyl 4-((1-(3,4-diiodobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

Methyl 4-((1-(3,5-diiodobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

15 Ethyl 4-((1-(2-fluorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

Ethyl 4-((1-(3-fluorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

20 Ethyl 4-((1-(4-fluorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

Ethyl 4-((1-(2,3-difluorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

Ethyl 4-((1-(2,4-difluorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

25 Ethyl 4-((1-(2,5-difluorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

Ethyl 4-((1-(2,6-difluorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

30 Ethyl 4-((1-(3,4-difluorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

Ethyl 4-((1-(3,5-difluorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

- Ethyl 4-((1-(2-chlorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- Ethyl 4-((1-(3-chlorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- 5 Ethyl 4-((1-(4-chlorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- Ethyl 4-((1-(2,3-dichlorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- Ethyl 4-((1-(2,4-dichlorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- 10 Ethyl 4-((1-(2,5-dichlorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- Ethyl 4-((1-(2,6-dichlorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- 15 Ethyl 4-((1-(3,4-dichlorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- Ethyl 4-((1-(3,5-dichlorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- Ethyl 4-((1-(2-bromobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- 20 Ethyl 4-((1-(3-bromobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- Ethyl 4-((1-(4-bromobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- 25 Ethyl 4-((1-(2,3-dibromobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- Ethyl 4-((1-(2,4-dibromobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- Ethyl 4-((1-(2,5-dibromobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- 30 Ethyl 4-((1-(2,6-dibromobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

- Ethyl 4-((1-(3,4-dibromobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- Ethyl 4-((1-(3,5-dibromobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- 5 Ethyl 4-((1-(2-iodobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- Ethyl 4-((1-(3-iodobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- Ethyl 4-((1-(4-iodobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- 10 Ethyl 4-((1-(2,3-diiodobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- Ethyl 4-((1-(2,4-diiodobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- 15 Ethyl 4-((1-(2,5-diiodobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- Ethyl 4-((1-(2,6-diiodobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- Ethyl 4-((1-(3,4-diiodobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- 20 Ethyl 4-((1-(3,5-diiodobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- tert*-Butyl 4-((1-(2-fluorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- 25 *tert*-Butyl 4-((1-(3-fluorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- tert*-Butyl 4-((1-(4-fluorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- tert*-Butyl 4-((1-(2,3-difluorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- 30 *tert*-Butyl 4-((1-(2,4-difluorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

- tert*-Butyl 4-((1-(2,5-difluorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- tert*-Butyl 4-((1-(2,6-difluorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- 5 *tert*-Butyl 4-((1-(3,4-difluorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- tert*-Butyl 4-((1-(3,5-difluorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- tert*-Butyl 4-((1-(2-chlorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- 10 *tert*-Butyl 4-((1-(3-chlorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- tert*-Butyl 4-((1-(4-chlorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- 15 *tert*-Butyl 4-((1-(2,3-dichlorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- tert*-Butyl 4-((1-(2,4-dichlorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- tert*-Butyl 4-((1-(2,5-dichlorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- 20 *tert*-Butyl 4-((1-(2,6-dichlorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- tert*-Butyl 4-((1-(3,4-dichlorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- 25 *tert*-Butyl 4-((1-(3,5-dichlorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- tert*-Butyl 4-((1-(2-bromobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- tert*-Butyl 4-((1-(3-bromobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- 30 *tert*-Butyl 4-((1-(4-bromobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

- tert*-Butyl 4-((1-(2,3-dibromobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- tert*-Butyl 4-((1-(2,4-dibromobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- 5 *tert*-Butyl 4-((1-(2,5-dibromobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- tert*-Butyl 4-((1-(2,6-dibromobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- 10 *tert*-Butyl 4-((1-(3,4-dibromobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- tert*-Butyl 4-((1-(3,5-dibromobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- tert*-Butyl 4-((1-(2-iodobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- 15 *tert*-Butyl 4-((1-(3-iodobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- tert*-Butyl 4-((1-(4-iodobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- 20 *tert*-Butyl 4-((1-(2,3-diiodobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- tert*-Butyl 4-((1-(2,4-diiodobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- tert*-Butyl 4-((1-(2,5-diiodobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- 25 *tert*-Butyl 4-((1-(2,6-diiodobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- tert*-Butyl 4-((1-(3,4-diiodobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- tert*-Butyl 4-((1-(3,5-diiodobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- 30 Methyl 4-((1-(2-methylbenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

- Methyl 4-((1-(3-methylbenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- Methyl 4-((1-(4-methylbenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- 5 Methyl 4-((1-(2,3-dimethylbenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- Methyl 4-((1-(2,4-dimethylbenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- Methyl 4-((1-(2,5-dimethylbenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- 10 Methyl 4-((1-(2,6-dimethylbenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- Methyl 4-((1-(3,4-dimethylbenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- 15 Methyl 4-((1-(3,5-dimethylbenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- Methyl 4-((1-(2-methoxybenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- Methyl 4-((1-(3-methoxybenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- 20 Methyl 4-((1-(4-methoxybenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- Methyl 4-((1-(2,3-dimethoxybenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- 25 Methyl 4-((1-(2,4-dimethoxybenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- Methyl 4-((1-(2,5-dimethoxybenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- Methyl 4-((1-(2,6-dimethoxybenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- 30 Methyl 4-((1-(3,4-dimethoxybenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

- Methyl 4-((1-(3,5-dimethoxybenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- Ethyl 4-((1-(2-methylbenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- 5 Ethyl 4-((1-(3-methylbenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- Ethyl 4-((1-(4-methylbenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- Ethyl 4-((1-(2,3-dimethylbenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- 10 Ethyl 4-((1-(2,4-dimethylbenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- Ethyl 4-((1-(2,5-dimethylbenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- 15 Ethyl 4-((1-(2,6-dimethylbenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- Ethyl 4-((1-(3,4-dimethylbenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- Ethyl 4-((1-(3,5-dimethylbenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- 20 Ethyl 4-((1-(2-methoxybenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- Ethyl 4-((1-(3-methoxybenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- 25 Ethyl 4-((1-(4-methoxybenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- Ethyl 4-((1-(2,3-dimethoxybenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- Ethyl 4-((1-(2,4-dimethoxybenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- 30 Ethyl 4-((1-(2,5-dimethoxybenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

- Ethyl 4-((1-(2,6-dimethoxybenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- Ethyl 4-((1-(3,4-dimethoxybenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- 5 Ethyl 4-((1-(3,5-dimethoxybenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- tert*-Butyl 4-((1-(2-methylbenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- tert*-Butyl 4-((1-(3-methylbenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- 10 *tert*-Butyl 4-((1-(4-methylbenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- tert*-Butyl 4-((1-(2,3-dimethylbenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- 15 *tert*-Butyl 4-((1-(2,4-dimethylbenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- tert*-Butyl 4-((1-(2,5-dimethylbenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- tert*-Butyl 4-((1-(2,6-dimethylbenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- 20 *tert*-Butyl 4-((1-(3,4-dimethylbenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- tert*-Butyl 4-((1-(3,5-dimethylbenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- 25 *tert*-Butyl 4-((1-(2-methoxybenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- tert*-Butyl 4-((1-(3-methoxybenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- tert*-Butyl 4-((1-(4-methoxybenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- 30 *tert*-Butyl 4-((1-(2,3-dimethoxybenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

tert-Butyl 4-((1-(2,4-dimethoxybenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

tert-Butyl 4-((1-(2,5-dimethoxybenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;


5 *tert*-Butyl 4-((1-(2,6-dimethoxybenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;

tert-Butyl 4-((1-(3,4-dimethoxybenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate; and

10 *tert*-Butyl 4-((1-(3,5-dimethoxybenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate.

In one aspect, the present disclosure provides a process for preparing a compound, the process comprising:

A) reacting 3-hydroxypyridin-2(1*H*)-one with a benzylating agent having the formula:




15 wherein X is a leaving group;

in the presence of:


i) an amount of a silylating reagent that provides at least 2 equivalents of a silyl protecting group; and

20 ii) a proton source;


to form a N-benzyl-3-hydroxypyridin-2(1*H*)-one having the formula:




B) reacting the N-benzyl-3-hydroxypyridin-2(1*H*)-one formed in Step (A) with a compound having the formula:



in the presence of a source of formaldehyde and an acid to form a product comprising a compound having the formula of Formula (I):



5 wherein Z is a substituted or unsubstituted phenyl ring having the formula:



the index n is an integer from 0 to 5;


each R is independently:

- i) C₁-C₆ linear, C₃-C₆ branched or C₃-C₆ cyclic alkyl;
- 10 ii) C₁-C₆ linear, C₃-C₆ branched or C₃-C₆ cyclic alkoxy;
- iii) halogen; or
- iv) cyano; and


R¹ is C₁ – C₄ linear or C₃ – C₄ branched alkyl.

15 The present disclosure also provides a process for preparing tert-butyl 4-((1-(4-chlorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate, comprising,


A) reacting 3-hydroxypyridin-2(1*H*)-one having the formula:



20 with 4-chlorobenzyl chloride having the formula:




in the presence of two equivalents of a silylating reagent, a proton source and a salt of a mineral acid to form 1-(4-chlorobenzyl)-3-hydroxypyridin-2(1*H*)-one having the formula:



5


B) reacting 1-(4-chlorobenzyl)-3-hydroxypyridin-2(1*H*)-one with *tert*-butyl piperazine-1-carboxylate having the formula:



;

in the presence of aqueous formaldehyde and a protic acid to form a product

10 comprising *tert*-butyl 4-((1-(4-chlorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate having the formula:




PROCESS

The disclosed process is outlined herein below in Scheme I.


Scheme I

Step A




5

Step B




Step A

10 Step A relates to the benzylation of 3-hydroxypyridin-2(1H)-one (2,3-dihydroxypyridine) at the pyridin-2(1H)-one ring nitrogen with a benzylating agent having the formula:




wherein X is a leaving group. Non-limiting examples of leaving groups include chloro, bromo, iodo, tosyl, mesyl and the like. R and the index n are defined herein above.

The reaction depicted in step A is carried out under modified Silyl-Hilbert-Johnson conditions. Without wishing to be limited by theory, the reaction depicted in Step A includes formation of di-silylated intermediate. This di-protected intermediate prevents undesired O-benylation of the 3-hydroxy and 2-hydroxy units of the pyridine tautomeric form 3-hydroxypyridin-2(1*H*)-one by the benzylating agent **A-1**. The resulting bis-silyl protected intermediate has the formula:



wherein P represents a silyl protecting group. Scheme II below summarizes a non-limiting example of Step A wherein two equivalents of hexamethyldisilazane are used to form intermediate **A-i**.

Scheme II



Step A(i) relates to the addition of at least about 2 equivalents of a silylating reagent to form a bis-O-silyl intermediate or a least one equivalent of a silylating reagent that can provide two equivalents of a silyl protecting group to form an intermediate such as **A-i** as depicted in the example set forth in Scheme II. In one non-limiting example, this intermediate can be formed by the reaction of bis(trimethylsilyl)amine (HMDS) with 3-hydroxypyridin-2(1*H*)-one. As indicated, intermediate **A-i** is not isolated, but is converted to intermediate **A-ii** *in situ* by the addition of reagent **A-1** during step A(ii). Also as indicated in Scheme II, product **A-ii** is also not isolated. Aqueous work-up removes the silyl protecting groups allowing the pyridinium salt **A-ii** to collapse and tautomerize to the

3-hydroxy-pyridin-2(1*H*)-one form and thereby liberate N-benzyl-3-hydroxypyridin-2(1*H*)-ones having the formula **A-2**.


Step A can be conducted with any a silylating reagent in an amount wherein the agent provides two or more equivalents of protecting group. For example, one equivalent of hexamethyldisilazane provides two equivalents of a silyl protecting group. In one embodiment of the disclosed process, hexamethyldisilazane is used as the silylating reagent. Non-limiting examples of silylating reagents include trimethylsilyl chloride, *tert*-butyl dimethylsilyl chloride, trimethylsilylimidazole, N,O-bis(trimethylsilyl)acetamide, N,N'-bis(trimethylsilyl)urea, N,O-bis(trimethylsilyl)trifluoroacetamide, heptamethyldisilazane, 1,1,3,3,-tetramethyl-1,3-divinyl-disilazane, and the like.

Step A is conducted in the presence of a source of proton, *i.e.*, a strong or weak protic acid as well as some salts of strong mineral acids. Typically the acid is present in a catalytic amount. In one embodiment, the source of proton is ammonium sulfate, (NH₄)₂SO₄. In another embodiment, the acid is hydroiodic, HI, or hydrobromic acid, HBr. In another embodiment the acid is phosphoric acid, H₃PO₄, or sulfuric acid, H₂SO₄.

Step A can be conducted in the presence of any compatible solvent or mixture of compatible solvents. Non-limiting examples of solvents includes acetonitrile, tetrahydrofuran, dichloromethane, chloroform, 1,2-dichloroethane, 1,1,1-trichloroethane, toluene, m-xylene and mixtures thereof. In one embodiment, acetonitrile is used as the solvent.

In one embodiment of the disclosed process, the reactant **A-1** is activated toward nucleophilic attack by 3-hydroxypyridin-2(1*H*)-one. This is accomplished by replacing the original leaving group X with a leaving group X¹ which is more labile to attack by the 3-hydroxypyridin-2(1*H*)-one nitrogen. In one embodiment, an *in situ* Finkelstein reaction is used to activate the leaving group. A non-limiting example of the formation of an activated benzylating agent is depicted herein below in Scheme III.


Scheme III



Step B

Step B relates to a Mannich Reaction between the N-benzyl-3-hydroxypyridin-2(1H)-one formed in Step A and a 4-carbamoylpiperazine, **B-1**. Step B is depicted in Scheme IV below.


Scheme IV



Without wishing to be limited by theory, Step B of the disclosed process involves the condensation of A-2 with B-1 in the presence of formaldehyde under standard Mannich Reaction conditions. The *in situ* generated imine of **B-1** reacts with intermediate **A-2** according to the proposed Scheme V herein below.

10

Scheme V



Intermediate A-2 and adduct B-1 are combined together with a source of formaldehyde and a protic acid. The reaction can be conducted at room temperature or at any temperature at or below reflux depending upon the choice of an optional solvent.

15

The reaction can be conducted in the presence of a compatible solvent. Non-limiting examples of solvents include water, formic acid, acetic acid; alcohols, for example, methanol, ethanol, 2,2,2-trichlorethanol, propanol, isopropanol, butanol, *tert*-butanol, and


the like; esters, for example, methyl acetate, ethyl acetate, methyl propionate, ethyl propionate, and the like; ethers, for example, diethyl ether, methyl *tert*-butyl ether, tetrahydrofuran, dimethoxyethane, bis(2-methoxyethyl) ether (diglyme), 1,4-dioxane, and the like; alkanes, for example, pentane, isopentane, petroleum ether, hexane, mixtures of hexanes, cyclohexane, heptanes, isoheptane, octane, isooctane, and the like; halogenated solvents, for example, dichloromethane, chloroform, carbon tetrachloride, 1,1-dichloroethane, 1,1,1-trichloroethane, 1,2-dichloroethane, chlorobenzene, and the like; aromatic hydrocarbons, for example, benzene, toluene, 1,2-dimethylbenzene (*ortho*-xylene), 1,3-dimethylbenzene (*meta*-xylene), 1,4-dimethylbenzene (*para*-xylene), nitrobenzene, and the like; dipolar aprotic solvents, for example, acetonitrile, dimethylsulfoxide, *N,N*-dimethylformamide, *N,N*-diethylformamide, *N,N*-dimethylacetamide, *N,N*-diethylacetamide, *N*-methyl-2-pyrrolidinone, carbon disulfide, and hexamethylphosphoramide; and mixtures of one or more solvents.

In one embodiment of the disclosed process the solvent is an alcohol, for example, methanol, ethanol, n-propanol or *iso*-propanol. In one non-limiting example ethanol is used as a solvent. The formulator can choose different alcohols depending upon the desired temperature to which the reaction is heated, for example, the temperature of reflux.


In one embodiment of the disclosed process the source of formaldehyde is a 37% weight percent solution in water. Other reagents which form or release formaldehyde or a formaldehyde equivalent can be used.

The following is a non-limiting example of the disclosed process as outlined in Scheme VI and depicted in Example 1.

Scheme VI



Reagents and conditions: (i) HMDS, (NH₄)SO₄; CH₃CN; reflux, 4 hr;
(ii) KI, 4-chlorobenzyl chloride.



Reagents and conditions: HCHO (aq.), AcOH, EtOH; 50 °C, 18 hr.

5

EXAMPLE 1

tert-Butyl 4-((1-(4-chlorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate (**3**)

Preparation of 1-(4-chlorobenzyl)-3-hydroxypyridin-2(1*H*)-one (**1**): to a nitrogen
 10 purged 1-L round bottom flask equipped with a mechanical stirrer, upright condenser, and
 thermometer was charged 3-hydroxypyridin-2(1*H*)-one [2,3-dihydroxypyridine] (40.0 g,
 0.36 mol, 1 equiv.) [CAS No. 16867-04-2], ammonium sulfate (2.4 g, 0.02 mol, 0.05
 equiv.) and acetonitrile (200 mL, 5 parts v/w). The resulting suspension was stirred at room
 temperature. Hexamethyldisilazane (116.2 g, 0.72 mol, 2 equiv.) is added dropwise. The
 15 resulting suspension was heated to reflux for 4 hours. The solution was then cooled to room
 temperature followed by the addition of a solution of 4-chlorobenzyl chloride (63.8 g, 0.4
 mol, 1.1 equiv.) in acetonitrile (40 mL, 1 part v/w). Potassium iodide (59.8 g, 0.36 mol, 1
 equiv.) is then added. The solution was then brought to reflux for 16 hours. The solution
 was cooled to 5 °C and water (240 mL) was slowly added over 15 minutes. The reaction
 20 mixture was allowed to warm to room temperature and stirring was continued for 2 hours.
 The solution was filtered under vacuum and rinsed with water (360 mL). The filter cake is
 then washed with methyl *tert*-butyl ether (360 mL). The resulting green-brown solid is
 vacuum dried to afford 63.5 g (86.2%) of the desired product. ¹H NMR (DMSO-*d*₆) δ ppm
 7.4 (d, 2H), 7.3 (d, 1H), 7.2 (d, 2H), 6.7 (d, 1H), 6.1 (t, 1H), and 5.1 (s, 2H).

25 Preparation of *tert*-butyl 4-((1-(4-chlorobenzyl)-3-hydroxy-2-oxo-1,2-
 dihydropyridin-4-yl)methyl)piperazine-1-carboxylate (**3**): to a nitrogen purged 2-L round


bottom flask equipped with a mechanical stirrer, upright condenser, and thermometer was charged 1-(4-chlorobenzyl)-3-hydroxypyridin-2(1*H*)-one (**1**) (50.0 g, 0.21 mol, 1 equiv.), *tert*-butyl piperazine-1-carboxylate, (**2**) (79.0 g, 0.42 mol, 2 equiv.) [CAS No. 57260-71-6] and ethanol (750 mL, 15 parts v/w). The solution was stirred and 37% aqueous
5 formaldehyde (34.7 mL, 0.47 mol, 2.2 equiv.) and acetic acid (36.4 mL, 0.64 mol, 3 equiv.) were added and the solution stirred for 1 hour after which the reaction solution was heated to 50 °C for 18 hours. The reaction mixture was then cooled below room temperature and filtered under vacuum. The resulting solid was rinsed with ethanol (250 mL) and dried under a stream of nitrogen to afford 77.2 g (83.9%) of the desired product. ¹H NMR
10 (DMSO-*d*₆) δ ppm 7.4 (d, 2H), 7.3 (d, 2H), 7.2 (d, 1H), 6.2 (d, 1H), 5.1 (s, 2H), 3.4-3.2 (m partly under brs water peak, 6H), 2.3 (m, 4H), 1.4 (s, 9H). ¹³C NMR (DMSO-*d*₆) [observed] δ ppm 157.24, 153.77, 144.36, 136.33, 132.15, 129.67, 128.48, 126.86, 124.56, 107.01, 78.74, 54.68, 52.49, 50.64, 43.48, and 28.03.

Other advantages which are obvious and which are inherent to the invention will be
15 evident to one skilled in the art.

What is claimed is:

1. A process for preparing a compound, the process comprising:

- A) reacting 3-hydroxypyridin-2(1*H*)-one with a benzylating agent having the formula:




wherein X is a leaving group;


in the presence of:

- i) an amount of a silylating reagent that provides at least 2 equivalents of a silyl protecting group; and
- ii) a proton source;

to form a N-benzy1-3-hydroxypyridin-2(1*H*)-one having the formula:



- B) reacting the N-benzy1-3-hydroxypyridin-2(1*H*)-one formed in Step (A) with a compound having the formula:



in the presence of a source of formaldehyde and an acid to form a product comprising a compound having the formula of Formula (I):



the index n is an integer from 0 to 5;

A benzene ring with a wavy line on the left and a substituent $(R)_n$ on the right.

- R¹ is C₁ – C₄ linear or C₃ – C₄ branched alkyl.

- 25

7. The process according to Claim 1, wherein R is C₁-C₆ linear, C₃-C₆ branched or C₃-C₆ cyclic alkyl.

8. The process according to Claim 1, wherein Z is chosen from 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 2-ethylphenyl, 3-ethylphenyl, 4-ethylphenyl, 2-(n-propyl)phenyl, 3-(n-propyl)phenyl, 4-(n-propyl)phenyl, 2-(n-butyl)phenyl, 3-(n-butyl)phenyl, 4-(n-butyl)phenyl, 2-(n-pentyl)phenyl, 3-(n-pentyl)phenyl, 4-(n-pentyl)phenyl, 2-(n-hexyl)phenyl, 3-(n-hexyl)phenyl, 4-(n-hexyl)phenyl, 2-(*iso*-propyl)phenyl, 3-(*iso*-propyl)phenyl, 4-(*iso*-propyl)phenyl, 2-(*iso*-butyl)phenyl, 3-(*iso*-butyl)phenyl, 4-(*iso*-butyl)phenyl, 2-(*sec*-butyl)phenyl, 3-(*sec*-butyl)phenyl, 4-(*sec*-butyl)phenyl, 2-(*tert*-butyl)phenyl, 3-(*tert*-butyl)phenyl, 4-(*tert*-butyl)phenyl, 2-(*iso*-pentyl)phenyl, 3-(*iso*-pentyl)phenyl, 4-(*iso*-pentyl)phenyl, 2-(*iso*-hexyl)phenyl, 3-(*iso*-hexyl)phenyl, and 4-(*iso*-hexyl)phenyl.

9. The process according to Claim 1, wherein R is C₁-C₆ linear, C₃-C₆ branched or C₃-C₆ cyclic alkoxy.

10. The process according to Claim 1, wherein Z is chosen from 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-ethoxyphenyl, 3-ethoxyphenyl, 4-ethoxyphenyl, 2-(n-propoxy)phenyl, 3-(n-propoxy)phenyl, 4-(n-propoxy)phenyl, 2-(n-butoxy)phenyl, 3-(n-butoxy)phenyl, 4-(n-butoxy)phenyl, 2-(n-pentyloxy)phenyl, 3-(n-pentyloxy)phenyl, 4-(n-pentyloxy)phenyl, 2-(n-hexyloxy)phenyl, 3-(n-hexyloxy)phenyl, 4-(n-hexyloxy)phenyl, 2-(*iso*-propoxy)phenyl, 3-(*iso*-propoxy)phenyl, 4-(*iso*-propoxy)phenyl, 2-(*iso*-butoxy)phenyl, 3-(*iso*-butoxy)phenyl, 4-(*iso*-butoxy)phenyl, 2-(*sec*-butoxy)phenyl, 3-(*sec*-butoxy)phenyl, 4-(*sec*-butoxy)phenyl, 2-(*tert*-butoxy)phenyl, 3-(*tert*-butoxy)phenyl, 4-(*tert*-butoxy)phenyl, 2-(*iso*-pentyloxy)phenyl, 3-(*iso*-pentyloxy)phenyl, 4-(*iso*-pentyloxy)phenyl, 2-(*iso*-hexyloxy)phenyl, 3-(*iso*-hexyloxy)phenyl, 4-(*iso*-hexyloxy)phenyl, 2,3-difluorophenyl, 2,4-difluorophenyl, 2,5-difluorophenyl, 2,6-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2,3,4-trifluorophenyl, 2,3,5-trifluorophenyl, 2,4,6-trifluorophenyl, 3,4,5-trifluorophenyl, 2,3,4,5-tetrafluorophenyl, 2,3,4,6-tetrafluorophenyl, 2,3,4,5,6-pentafluorophenyl, 2,3-dichlorophenyl, 2,4-dichlorophenyl, 2,5-dichlorophenyl, 2,6-dichlorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 2,3,4-trichlorophenyl, 2,3,5-trichlorophenyl, 2,4,6-trichlorophenyl, 3,4,5-trichlorophenyl, 2,3,4,5-tetrachlorophenyl, 2,3,4,6-tetra-chlorophenyl, 2,3,4,5,6-pentachlorophenyl, 2,3-dibromophenyl, 2,4-dibromophenyl, 2,5-dibromophenyl, 2,6-dibromophenyl, 3,4-dibromophenyl, 3,5-dibromophenyl, 2,3,4-tribromophenyl, 2,3,5-tribromophenyl, 2,4,6-tribromophenyl, 3,4,5-tribromophenyl, 2,3,4,5-tetrabromophenyl, 2,3,4,6-tetra-bromophenyl, 2,3,4,5,6-pentabromophenyl, 2,3-diiodophenyl, 2,4-diiodophenyl, 2,5-diiodophenyl, 2,6-diiodophenyl,

3,4-diiodophenyl, 3,5-diiodophenyl, 2,3,4-triiodophenyl, 2,3,5-triiodophenyl, 2,4,6-triiodophenyl, 3,4,5-triiodophenyl, 2,3,4,5-tetraiodophenyl, 2,3,4,6-tetraiodophenyl, 2,3,4,5,6-pentaiodophenyl, 2,3-dimethylphenyl, 2,4-dimethylphenyl, 2,5-dimethylphenyl, 2,6-dimethylphenyl, 3,4-dimethylphenyl, 3,5-dimethylphenyl, 2,3,4-trimethylphenyl, 2,3,5-trimethylphenyl, 2,4,6-trimethylphenyl, 3,4,5-trimethylphenyl, 2,3,4,5-tetramethylphenyl, 2,3,4,6-tetramethylphenyl, 2,3,4,5,6-pentamethylphenyl, 2,3-diethylphenyl, 2,4-diethylphenyl, 2,5-diethylphenyl, 2,6-diethylphenyl, 3,4-diethylphenyl, 3,5-diethylphenyl, 2,3,4-triethylphenyl, 2,3,5-triethylphenyl, 2,4,6-triethylphenyl, 3,4,5-triethylphenyl, 2,3,4,5-tetraethylphenyl, 2,3,4,6-tetraethylphenyl, 2,3,4,5,6-pentaethylphenyl, 2,3-dibromophenyl, 2,4-dibromophenyl, 2,5-dibromophenyl, 2,6-dibromophenyl, 3,4-dibromophenyl, 3,5-dibromophenyl, 2,3,4-tribromophenyl, 2,3,5-tri(n-propyl)phenyl, 2,4,6-tri(n-propyl)phenyl, 3,4,5-tri(n-propyl)phenyl, 2,3,4,5-tetra(n-propyl)phenyl, 2,3,4,6-tetra(n-propyl)phenyl, 2,3,4,5,6-penta(n-propyl)phenyl, 2,3-di(n-butyl)phenyl, 2,4-di(n-butyl)phenyl, 2,5-di(n-butyl)phenyl, 2,6-di(n-butyl)phenyl, 3,4-di(n-butyl)phenyl, 3,5-di(n-butyl)phenyl, 2,3,4-tri(n-butyl)phenyl, 2,3,5-tri(n-butyl)phenyl, 2,4,6-tri(n-butyl)phenyl, 3,4,5-tri(n-butyl)phenyl, 2,3,4,5-tetra(n-butyl)phenyl, 2,3,4,6-tetra(n-butyl)phenyl, and 2,3,4,5,6-penta(n-butyl)phenyl.

11. The process according to Claim 1, wherein at least one R is chosen from C₁-C₆ linear, C₃-C₆ branched and C₃-C₆ cyclic alkyl and at least one R is halogen.

12. The process according to Claim 1, wherein at least one R is chosen from C₁-C₆ linear, C₃-C₆ branched and C₃-C₆ cyclic alkoxy and at least one R is halogen.

13. The process according to Claim 1, wherein at least one R is chosen from C₁-C₆ linear, C₃-C₆ branched and C₃-C₆ cyclic alkyl and at least one R is chosen from C₁-C₆ linear, C₃-C₆ branched and C₃-C₆ cyclic alkoxy.


14. The process according to Claim 1, wherein the benzylating agent has the formula:

;


wherein the leaving group X is chosen from chloro, bromo, iodo, tosyl, and mesyl.

15. The process according Claim 14, wherein the leaving group X is chloro.


16. The process according to Claim 14, wherein the leaving group X is iodo.
17. The process according to Claim 1, wherein the number of equivalents of silylating reagent in Step (A) is from 2 to about 4.
18. The process according to Claim 1, wherein the proton source in Step (A) is ammonium sulfate.
19. The process according to Claim 1, wherein the source of formaldehyde is an aqueous solution of formaldehyde.
20. A process for preparing *tert*-butyl 4-((1-(4-chlorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate, comprising,
- A) reacting 3-hydroxypyridin-2(1*H*)-one having the formula:




with 4-chlorobenzyl chloride having the formula:




in the presence of two equivalents of a silylating reagent, a proton source and a salt of a mineral acid to form 1-(4-chlorobenzyl)-3-hydroxypyridin-2(1*H*)-one having the formula:



B) reacting 1-(4-chlorobenzyl)-3-hydroxypyridin-2(1*H*)-one with *tert*-butyl piperazine-1-carboxylate having the formula:



in the presence of aqueous formaldehyde and a protic acid to form a product comprising *tert*-butyl 4-((1-(4-chlorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate having the formula:



21. The process according to Claim 20, wherein the silylating reagent is hexamethyldisilazane.
22. The process according to Claim 20, wherein the proton source in Step (A) is ammonium sulfate.
23. The process according to Claim 20, wherein the protic acid in Step (B) is acetic acid.
24. The process according to claim 20, wherein the salt of a mineral acid is potassium iodide.
25. The process according to claim 20, wherein the product further comprises acetate.
26. The process according to claim 1, wherein R¹ is C₁-C₄ linear or C₃-C₄ branched alkyl.
27. The process according to claim 1, wherein the product further comprises acetate.

28. The process according to claim 1, wherein the silylating reagent is hexamethyldisilazane.

29. The process according to claim 1, wherein the acid in Step (B) is acetic acid.